LNTH vs. VRTX

Last updated Apr 1, 2026

Compare and contrast key facts about Lantheus Holdings, Inc. (LNTH) and Vertex Pharmaceuticals Incorporated (VRTX).

Performance

LNTH vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lantheus Holdings, Inc. (LNTH) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

LNTH vs. VRTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LNTH Lantheus Holdings, Inc.	13.97%	-25.61%	44.29%	21.66%	76.39%	114.16%	-34.23%	31.05%	-23.47%	137.79%
VRTX Vertex Pharmaceuticals Incorporated	-1.50%	12.58%	-1.03%	40.90%	31.50%	-7.08%	7.94%	32.13%	10.58%	103.42%

Fundamentals

Market Cap LNTH : $5.03B VRTX : $114.36B
EPS LNTH : $3.43 VRTX : $15.35
PE Ratio LNTH : 22.11 VRTX : 29.09
PEG Ratio LNTH : 0.09 VRTX : 2.42
PS Ratio LNTH : 3.35 VRTX : 9.58
PB Ratio LNTH : 4.62 VRTX : 6.13
Total Revenue (TTM) LNTH : $1.54B VRTX : $12.00B
Gross Profit (TTM) LNTH : $941.95M VRTX : $10.35B
EBITDA (TTM) LNTH : $382.55M VRTX : $4.74B

Returns By Period

In the year-to-date period, LNTH achieves a 13.97% return, which is significantly higher than VRTX's -1.50% return. Over the past 10 years, LNTH has outperformed VRTX with an annualized return of 44.66%, while VRTX has yielded a comparatively lower 18.89% annualized return.

LNTH

• 1D: 3.78%
• 1M: 1.25%
• YTD: 13.97%
• 6M: 47.88%
• 1Y: -22.28%
• 3Y*: -2.79%
• 5Y*: 29.28%
• 10Y*: 44.66%

VRTX

• 1D: 0.76%
• 1M: -10.12%
• YTD: -1.50%
• 6M: 14.02%
• 1Y: -7.90%
• 3Y*: 12.33%
• 5Y*: 15.95%
• 10Y*: 18.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LNTH vs. VRTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LNTH

LNTH Risk / Return Rank: 27
LNTH Sharpe Ratio Rank: 23
LNTH Sortino Ratio Rank: 25
LNTH Omega Ratio Rank: 24
LNTH Calmar Ratio Rank: 30
LNTH Martin Ratio Rank: 33

VRTX

VRTX Risk / Return Rank: 31
VRTX Sharpe Ratio Rank: 32
VRTX Sortino Ratio Rank: 29
VRTX Omega Ratio Rank: 29
VRTX Calmar Ratio Rank: 32
VRTX Martin Ratio Rank: 31

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LNTH vs. VRTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lantheus Holdings, Inc. (LNTH) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LNTH	VRTX	Difference
Sharpe ratio Return per unit of total volatility	-0.43	-0.22	-0.20
Sortino ratio Return per unit of downside risk	-0.23	-0.05	-0.17
Omega ratio Gain probability vs. loss probability	0.96	0.99	-0.03
Calmar ratio Return relative to maximum drawdown	-0.39	-0.33	-0.06
Martin ratio Return relative to average drawdown	-0.56	-0.65	+0.10
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LNTH vs. VRTX - Sharpe Ratio Comparison

The current LNTH Sharpe Ratio is -0.43, which is lower than the VRTX Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of LNTH and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LNTH	VRTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.43	-0.22	-0.20
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.51	0.56	-0.04
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.72	0.57	+0.15
Sharpe Ratio (All Time) Calculated using the full available price history	0.39	0.26	+0.13

Correlation

The correlation between LNTH and VRTX is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LNTH vs. VRTX - Dividend Comparison

Neither LNTH nor VRTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

LNTH vs. VRTX - Drawdown Comparison

The maximum LNTH drawdown since its inception was -78.62%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for LNTH and VRTX.

Drawdown Indicators

	LNTH	VRTX	Difference
Max Drawdown Largest peak-to-trough decline	-78.62%	-91.77%	+13.15%
Max Drawdown (1Y) Largest decline over 1 year	-53.92%	-28.06%	-25.86%
Max Drawdown (5Y) Largest decline over 5 years	-59.46%	-29.07%	-30.39%
Max Drawdown (10Y) Largest decline over 10 years	-68.52%	-41.60%	-26.92%
Current Drawdown Current decline from peak	-38.64%	-13.59%	-25.05%
Average Drawdown Average peak-to-trough decline	-28.22%	-37.81%	+9.59%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.92%	14.33%	+23.59%

Volatility

LNTH vs. VRTX - Volatility Comparison

Lantheus Holdings, Inc. (LNTH) has a higher volatility of 15.01% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 11.93%. This indicates that LNTH's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LNTH	VRTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.01%	11.93%	+3.08%
Volatility (6M) Calculated over the trailing 6-month period	25.31%	21.67%	+3.64%
Volatility (1Y) Calculated over the trailing 1-year period	52.54%	35.83%	+16.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.33%	28.77%	+28.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.10%	33.24%	+28.86%

Financials

LNTH vs. VRTX - Profitability Comparison

The chart below illustrates the profitability comparison between Lantheus Holdings, Inc. and Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LNTH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Lantheus Holdings, Inc. reported a gross profit of 240.88M and revenue of 406.79M. Therefore, the gross margin over that period was 59.2%.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.72B and revenue of 3.19B. Therefore, the gross margin over that period was 85.4%.

LNTH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Lantheus Holdings, Inc. reported an operating income of 77.18M and revenue of 406.79M, resulting in an operating margin of 19.0%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.26B and revenue of 3.19B, resulting in an operating margin of 39.6%.

LNTH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Lantheus Holdings, Inc. reported a net income of 54.09M and revenue of 406.79M, resulting in a net margin of 13.3%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.19B and revenue of 3.19B, resulting in a net margin of 37.3%.